Literature DB >> 12387703

Antioxidants as treatment for neurodegenerative disorders.

Bernd Moosmann1, Christian Behl.   

Abstract

Oxidative stress is a ubiquitously observed hallmark of neurodegenerative disorders. Neuronal cell dysfunction and cell death due to oxidative stress may causally contribute to the pathogenesis of progressive neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as acute syndromes of neurodegeneration, such as ischaemic and haemorrhagic stroke. Neuroprotective antioxidants are considered a promising approach to slowing the progression and limiting the extent of neuronal cell loss in these disorders. The clinical evidence demonstrating that antioxidant compounds can act as protective drugs in neurodegenerative disease, however, is still relatively scarce. In the following review, the available data from clinical, animal and cell biological studies regarding the role of antioxidant neuroprotection in progressive neurodegenerative disease will be summarised, focussing particularly on Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. The general complications in developing potent neuroprotective antioxidant drugs directed against these long-term degenerative conditions will also be discussed. The major challenges for drug development are the slow kinetics of disease progression, the unsolved mechanistic questions concerning the final causalities of cell death, the necessity to attain an effective permeation of the blood-brain barrier and the need to reduce the high concentrations currently required to evoke protective effects in cellular and animal model systems. Finally, an outlook as to which direction antioxidant drug development and clinical practice may be leading to in the near future will be provided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387703     DOI: 10.1517/13543784.11.10.1407

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  52 in total

Review 1.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

2.  Inactivation of nitric oxide by rat cerebellar slices.

Authors:  C N Hall; J Garthwaite
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 3.  Amyloid-β production: major link between oxidative stress and BACE1.

Authors:  Elena Tamagno; Michela Guglielmotto; Debora Monteleone; Massimo Tabaton
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

Review 4.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

5.  Neuroprotective effect of etomidate in the central nervous system of streptozotocin-induced diabetic rats.

Authors:  Ozkan Ates; Neslihan Yucel; Suleyman R Cayli; Eyup Altinoz; Saim Yologlu; Ayhan Kocak; Celal Ozbek Cakir; Yusuf Turkoz
Journal:  Neurochem Res       Date:  2006-06-21       Impact factor: 3.996

Review 6.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

7.  Free radical scavengers vitamins A, C, and E plus magnesium reduce noise trauma.

Authors:  Colleen G Le Prell; Larry F Hughes; Josef M Miller
Journal:  Free Radic Biol Med       Date:  2007-02-20       Impact factor: 7.376

8.  Effect of intrahippocampal administration of vitamin C and progesterone on learning in a model of multiple sclerosis in rats.

Authors:  Shirin Babri; Faezeh Mehrvash; Gisou Mohaddes; Homeira Hatami; Fariba Mirzaie
Journal:  Adv Pharm Bull       Date:  2015-03-05

9.  Why Have Clinical Trials of Antioxidants to Prevent Neurodegeneration Failed? - A Cellular Investigation of Novel Phenothiazine-Type Antioxidants Reveals Competing Objectives for Pharmaceutical Neuroprotection.

Authors:  Maike J Ohlow; Selina Sohre; Matthias Granold; Mathias Schreckenberger; Bernd Moosmann
Journal:  Pharm Res       Date:  2016-11-28       Impact factor: 4.200

10.  Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.

Authors:  Michela Guglielmotto; Luca Giliberto; Elena Tamagno; Massimo Tabaton
Journal:  Front Aging Neurosci       Date:  2010-02-09       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.